562 related articles for article (PubMed ID: 18266225)
21. High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results.
Comandone A; Passera R; Boglione A; Tagini V; Ferrari S; Cattel L
Acta Oncol; 2005; 44(4):406-11. PubMed ID: 16120550
[TBL] [Abstract][Full Text] [Related]
22. High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how?
Sterba J; Valík D; Bajciová V; Kadlecová V; Gregorová V; Mendelová D
Neoplasma; 2005; 52(6):456-63. PubMed ID: 16284689
[TBL] [Abstract][Full Text] [Related]
23. Experience with high dose methotrexate therapy in childhood acute lymphoblastic leukemia in a tertiary care cancer centre of a developing country.
Kapoor G; Sinha R; Abedin S
Pediatr Blood Cancer; 2012 Sep; 59(3):448-53. PubMed ID: 22271707
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors in the response of primary osteogenic sarcoma to preoperative chemotherapy (high-dose methotrexate with citrovorum factor).
Juergens H; Kosloff C; Nirenberg A; Mehta BM; Huvos AG; Rosen G
Natl Cancer Inst Monogr; 1981 Apr; (56):221-6. PubMed ID: 6975439
[TBL] [Abstract][Full Text] [Related]
25. Essential laboratory determinations for monitoring high-dose methotrexate treatment with citrovorum factor rescue.
Jürgens H; Ebell W; Bachmann R; Kupke I; Richter O; Andräs A; Göbel U
Pediatr Pharmacol (New York); 1983; 3(3-4):157-65. PubMed ID: 6610851
[TBL] [Abstract][Full Text] [Related]
26. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma.
Delepine N; Delepine G; Cornille H; Brion F; Arnaud P; Desbois JC
Anticancer Res; 1995; 15(2):489-94. PubMed ID: 7763028
[TBL] [Abstract][Full Text] [Related]
27. Anaphylactoid reaction to high-dose methotrexate and successful desensitization.
Oulego-Erroz I; Maneiro-Freire M; Bouzón-Alejandro M; Vázquez-Donsión M; Couselo JM
Pediatr Blood Cancer; 2010 Sep; 55(3):557-9. PubMed ID: 20533520
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial.
Hamaguchi T; Shirao K; Yamamichi N; Hyodo I; Koizumi W; Seki S; Imamura T; Honma H; Ohtsu A; Boku N; Mukai T; Yamamoto S; Fukuda H; Yoshida S;
Jpn J Clin Oncol; 2008 Jun; 38(6):432-7. PubMed ID: 18515821
[TBL] [Abstract][Full Text] [Related]
29. Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma.
Jaffe N; Jorgensen K; Robertson R; George M; Letvak L; Barrett G
Anticancer Drugs; 1993 Oct; 4(5):559-64. PubMed ID: 8292813
[TBL] [Abstract][Full Text] [Related]
30. Weekly methotrexate (50mg/m(2)) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jun; 117(3):477-80. PubMed ID: 20347479
[TBL] [Abstract][Full Text] [Related]
31. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
32. Use of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiency.
Cecyn KZ; Lee J; Oguro T; Petrilli AS; Bordin JO
Am J Hematol; 2003 Mar; 72(3):209-11. PubMed ID: 12605394
[TBL] [Abstract][Full Text] [Related]
33. Renal dysfunction during and after high-dose methotrexate.
Green MR; Chamberlain MC
Cancer Chemother Pharmacol; 2009 Mar; 63(4):599-604. PubMed ID: 18504579
[TBL] [Abstract][Full Text] [Related]
34. Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma.
Bernard S; Hachon L; Diasonama JF; Madaoui C; Aguinaga L; Miekoutima E; Moatti H; Perrial E; Madelaine I; Brice P; Thieblemont C
Ann Hematol; 2021 Apr; 100(4):979-986. PubMed ID: 33608849
[TBL] [Abstract][Full Text] [Related]
35. Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience.
Garrett AP; Garner EO; Goldstein DP; Berkowitz RS
J Reprod Med; 2002 May; 47(5):355-62. PubMed ID: 12063874
[TBL] [Abstract][Full Text] [Related]
36. High-dose methotrexate with leucovorin rescue in ovarian cancer: a phase II study.
Parker LM; Griffiths CT; Yankee RA; Knapp RC; Canellos GP
Cancer Treat Rep; 1979 Feb; 63(2):275-9. PubMed ID: 312692
[TBL] [Abstract][Full Text] [Related]
37. [The influence of liver and renal functions on the changes in serum methotrexate (MTX) level in high-dose MTX therapy].
Sato T; Nakanishi K; Takahashi M; Sato K; Miura T; Kuzuya T; Mizuno M
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2375-9. PubMed ID: 2260874
[TBL] [Abstract][Full Text] [Related]
38. Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.
Nowicki TS; Bjornard K; Kudlowitz D; Sandoval C; Jayabose S
J Pediatr Hematol Oncol; 2008 Dec; 30(12):950-2. PubMed ID: 19131789
[TBL] [Abstract][Full Text] [Related]
39. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G
Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of low-dose methotrexate in advanced osteosarcoma followed by escalation after disease progression: a study of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research on Treatment of Cancer.
Wagener DJ; van Oosterom AT; Mulder JH; Somers R; Mouridsen HT; Cortes Funes H; Thomas D; Sylvester R
Cancer Treat Rep; 1986 May; 70(5):615-8. PubMed ID: 3458532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]